These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 25622075

  • 1. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, Yu H, Huang Y, Chen L, Xu M, Gu W, Li Y.
    Mol Pharm; 2015 Mar 02; 12(3):922-31. PubMed ID: 25622075
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Tom G, Philip S, Isaac R, Praseetha PK, Jiji SG, Asha VV.
    Life Sci; 2018 Aug 01; 206():10-21. PubMed ID: 29709652
    [Abstract] [Full Text] [Related]

  • 9. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, Jiang Z, Liu X, Liang Y, Ma D.
    Drug Deliv; 2018 Nov 01; 25(1):1484-1494. PubMed ID: 29916268
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J.
    Biomaterials; 2017 Oct 01; 143():1-16. PubMed ID: 28755539
    [Abstract] [Full Text] [Related]

  • 11. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N.
    Nanomedicine (Lond); 2017 Apr 01; 12(8):911-925. PubMed ID: 28339312
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
    Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D, Zhang J, Yu D, Zhang N.
    Colloids Surf B Biointerfaces; 2016 May 01; 141():83-92. PubMed ID: 26844644
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 01; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 14. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 15. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 16. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
    Zhao ZB, Long J, Zhao YY, Yang JB, Jiang W, Liu QZ, Yan K, Li L, Wang YC, Lian ZX.
    Biomater Sci; 2018 Mar 26; 6(4):893-900. PubMed ID: 29512660
    [Abstract] [Full Text] [Related]

  • 17. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Mar 26; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 18. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Sun W, Wang Y, Cai M, Lin L, Chen X, Cao Z, Zhu K, Shuai X.
    Biomater Sci; 2017 Nov 21; 5(12):2468-2479. PubMed ID: 29106433
    [Abstract] [Full Text] [Related]

  • 19. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    Yang S, Zhang B, Gong X, Wang T, Liu Y, Zhang N.
    Int J Nanomedicine; 2016 Nov 21; 11():2329-43. PubMed ID: 27307733
    [Abstract] [Full Text] [Related]

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.